Works matching IS 22351795 AND DT 2022 AND VI 11 AND IP 6

Results: 14

Front & Back Matter.

Published in:: Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 1, doi. 10.1159/000528495
Publication type:: Article

Contents Vol. 11, 2022.

Published in:: Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. I, doi. 10.1159/000528106
Publication type:: Article

APPLE News.

Published in:: Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 582, doi. 10.1159/000528105
Publication type:: Article

Acknowledgement to Reviewers.

Published in:: Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 583, doi. 10.1159/000527592
Publication type:: Article

Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects.

Published in:

Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 487, doi. 10.1159/000527404

By:

Kudo, Masatoshi

Publication type:

Article

Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab.

Published in:

Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 572, doi. 10.1159/000526388

By:

Endo, Kei;
Kuroda, Hidekatsu;
Oikawa, Takayoshi;
Ito, Yuma;
Abe, Tamami;
Kooka, Youhei;
Kakisaka, Keisuke;
Miyasaka, Akio;
Sugai, Tamotsu;
Matsumoto, Takayuki

Publication type:

Article

Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).

Published in:

Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 511, doi. 10.1159/000526038

By:

Yang, Yu;
Sun, Juxian;
Wu, Mengchao;
Lau, Wan Yee;
Zheng, Shusen;
Wang, Xue-Hao;
Chen, Xiaoping;
Fan, Jia;
Dong, Jiahong;
Cai, Jianqiang;
Chen, Minshan;
Chen, Yongjun;
Cheng, Zhangjun;
Dai, Chaoliu;
Shan, Jianzhen;
Du, Cheng-You;
Fang, Chihua;
Hu, Heping;
Ji, Zhili;
Jia, Weidong

Publication type:

Article

Response to the Article on Antibiotics and Immune Checkpoint Inhibitors by Lin et al.

Published in:

Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 578, doi. 10.1159/000526003

By:

Cheung, Ka Shing;
Leung, Wai K.

Publication type:

Article

Erratum.

Published in:: 2022
Publication type:: Correction Notice

Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial.

Published in:

Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 558, doi. 10.1159/000525671

By:

Li, Daneng;
Toh, Han Chong;
Merle, Philippe;
Tsuchiya, Kaoru;
Hernandez, Sairy;
Verret, Wendy;
Nicholas, Alan;
Kudo, Masatoshi

Publication type:

Article

Hepatitis B Virus Treatment and Hepatocellular Carcinoma: Controversies and Approaches to Consensus.

Published in:

Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 497, doi. 10.1159/000525518

By:

Kim, Soo Ki;
Fujii, Takako;
Kim, Soo Ryang;
Nakai, Atsushi;
Lim, Young-Suk;
Hagiwara, Satoru;
Kudo, Masatoshi

Publication type:

Article

Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?

Published in:

Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 540, doi. 10.1159/000525375

By:

Zaki, Marco Y.W.;
Alhasan, Sari F.;
Shukla, Ruchi;
McCain, Misti;
Laszczewska, Maja;
Geh, Daniel;
Patman, Gillian L.;
Televantou, Despina;
Whitehead, Anna;
Maurício, João P.;
Barksby, Ben;
Gee, Lucy M.;
Paish, Hannah L.;
Leslie, Jack;
Younes, Ramy;
Burt, Alastair D.;
Borthwick, Lee A.;
Thomas, Huw;
Beale, Gary S.;
Govaere, Olivier

Publication type:

Article

Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study.

Published in:

Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 527, doi. 10.1159/000525145

By:

Casadei-Gardini, Andrea;
Rimini, Margherita;
Kudo, Masatoshi;
Shimose, Shigeo;
Tada, Toshifumi;
Suda, Goki;
Goh, Myung Ji;
Jefremow, Andre;
Scartozzi, Mario;
Cabibbo, Giuseppe;
Campani, Claudia;
Tamburini, Emiliano;
Tovoli, Francesco;
Ueshima, Kazuomi;
Aoki, Tomoko;
Iwamoto, Hideki;
Torimura, Takuji;
Kumada, Takashi;
Hiraoka, Atsushi;
Atsukawa, Masanori

Publication type:

Article

Impact of Antibiotics Use on Cancer-Related and All-Cause Mortality among Patients Receiving Immunotherapy for Advanced Hepatocellular Carcinoma.

Published in:

Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 576, doi. 10.1159/000525028

By:

Lin, Kong-Ying;
Tang, Shi-Chuan;
Zhang, Cheng-Wu;
Zeng, Yong-Yi;
Yang, Tian

Publication type:

Article